BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...

The new test measures the risk of preeclampsia with up to 90% sensitivity and 90% specificity, according to Labcorp. Photo by Adobe Stock/HealthDay News Preeclampsia can be a life-threatening ...

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care Alzheimer's disease, the most prevalent form of dementia, poses a ...

Please provide your email address to receive an email when new articles are posted on . Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for ...

BURLINGTON – Global life science giant Labcorp is rolling out a test that it says can speed up a diagnosis for Alzheimer’s and thus lead to earlier intervention to fight the deadly disease. The test ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The logo for Labcorp is displayed on a screen on the floor of the NYSE in New York By Deena Beasley (Reuters) - ...

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...

Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

Labcorp, one of the country’s largest providers of diagnostic medical testing services, announced today that it will offer the only blood test cleared by the U.S. Food and Drug Administration to aid ...